NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
Dollar Rises as Middle East Conflict Fuels Inflation and Rate Hike Fears 
Singapore GDP Grows 5.7% in Q2 2026 as AI-Driven Manufacturing Boosts Economy 
Asia Stocks Slip as Iran-Hormuz Tensions Lift Oil Prices, Dollar and Bond Yields 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
US Inflation Expected to Ease in June, but Fed Rate Hike Risks Persist Amid Middle East Tensions 
Asian Stocks Slide as Oil Surge, U.S.-Iran Tensions and Fed Rate Bets Weigh on Markets 
China Trade Surplus Hits $125.6 Billion as June Exports, Imports Smash Forecasts 
Asian Currencies Weaken as Stronger Dollar Weighs, Yen Supported by GPIF Repatriation Hopes 
Goldman Sees Foreign Investors Driving India Stock Market Recovery 
Australia Consumer Sentiment Rises in July as Fuel Price Relief Lifts Confidence 
Dollar Holds Steady Ahead of U.S. CPI as Oil Surge, Middle East Tensions Keep Markets on Edge 
BOJ May Raise Japan Growth Forecast While Keeping Focus on Inflation Risks 
South Korea’s KOSPI Triggers Trading Curb as AI Chip Stock Selloff Deepens 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
